Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records
Introduction Schizophrenia is a chronic neuropsychiatric disorder which affects over 20 million people worldwide. Atypical antipsychotics are the first-line choice for the treatment of schizophrenia due to improved tolerability and diminished risk of extrapyramidal symptoms. Lurasidone is an atypic...
Main Authors: | C. De La Pinta, I. Gabarda |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-06-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822005442/type/journal_article |
Similar Items
-
Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
by: A. Jones, et al.
Published: (2022-06-01) -
Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice
by: Andrea Fagiolini, et al.
Published: (2022-12-01) -
Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
by: Amy Dymond, et al.
Published: (2022-08-01) -
Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
by: F. Calisti, et al.
Published: (2021-04-01) -
Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment
by: M. Tocco, et al.
Published: (2021-04-01)